CDl3/氨基肽酶N在新生血管成像中的应用价值

付彤; 瞿卫; 王峰

doi:10.3760,cma.j.issn.1673-4114.2011.06.001

付彤 , 瞿卫 , 王峰

文章导航 > 国际放射医学核医学杂志 > 2011, 35 > 6: (321-324)

引用本文:

Citation:

CDl3/氨基肽酶N在新生血管成像中的应用价值

南京医科大学附属南京第一医院核医学科, 210006

The application of CDl3/aminopeptidase N in the angiogenesis imaging

Department of Nuclear Medicine, Nanjing First Hospital Affiliated to Nanjing Medicine University, Nanjing 210006, China

摘要: 新生血管的发生在恶性肿瘤发生、发展和转移过程起着关键作用。CDl3是人类白血病分级的重要谱系特异性标志物,在新生血管内皮细胞上特异性高表达,在静止血管内皮细胞上不表达。利用荧光、核素标记或磁性纳米颗粒耦联CDl3单克隆抗体、配体,通过分子成像技术可有效探测新生血管的发生,为研究血管相关疾病的发生、发展提供影像学依据;CDl3的配体——天冬氨酸.甘氨酸一精氨酸与各种抗肿瘤药物构成复合物,然后转运到肿瘤新生血管内皮细胞表面与CDl3结合,释放抗肿瘤药物治疗肿瘤。CDl3在与新生血管相关的各类疾病的认识、诊断、治疗的研究中有着突破性进展和良好的前景。
- 新生血管化,病理性 /
- 抗原,CDl3 /
- 寡肽类 /
- 靶向追踪 /
- 抗肿瘤药
Abstract: The development and metasis of malignant tumor depend on neovascularization.CDl3 is a significant marker of cells commit to myeloid lineage to classify leukemia,meanwhile it expresses on the neovascular endothelial cells specifically but expresses barely in vascular endothelial cells.Coupling CDl3 monoclonal antibody or CDl3 ligand to CDl3 in fluorescence,radionuclide or magnetic nanoparticles to achieve molecular imaging to probe angiogenesis and provide imaging evidence of the development of angio-genesis associated disease.Asn-Gly-Arg peptide motif compound with different anticancer drugs targeted deliver to neovascular endothelial cells and release the anticancer drugs to treat the tumor.The research of CDl3 to understand,diagnose and treat the angiogenesis associated diseases has gotten breakthrough and have a promising future.
- Neovasculaiization,pathologic /
- Antigens,CDl3 /
- Oligopeptides /
- Target homing /
- Anti-neoplastic agents
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[l] Curnis F,Arrigoni G,Sacehi A,et al.Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels,epithelia,and myeloid cells.Cancer Res,2002,62(3):867-874.
[2]	Bhagwat SV,Lahdenranta J,Giordano R,et al.CD13/APN is activated by angiogenic signals and is essential for capillary tube formation.Blood,2001,97(3):652-659.
[3]	Bhagwat SV,Petrovic N,Okamoto Y,et al.The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis.Blood,2003,101(5):1818-1826.
[4]	吴旭辉.CD13靶向治疗研究进展.癌症进展,2006,4(2):163-166.
[5]	Corti A,Curnis F,Arap W,et al.The neovasculature homing motif NGR:more than meets the eye.Blood,2008,112(7):2628-2635.
[6]	Pasqualini R,Koivunen E,Kain R,et al.Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.Cancer Res,2000,60(3):722-727.
[7]	Di Matteo P,Arrigoni GL,Alberici L,et al.Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues.J His-tochem Cytochem,2011,59(1):47-59.
[8]	Carmeliet P.Angiogenesis in life,disease and medicine.Nature,2005.438(7070):932-936.
[9]	Carmeliet P,Jain RK.Angiogenesis in cancer and other diseases.Nature.2000,407(6801):249-257.
[10]	Fukasawa K Fujii H,Saitoh Y,et al.Aminopeptidase N(APN/CD13) is selectively expressed in vascular endothelial cells and plays mul-tiple role in angiogenesis.Cancer Lett,2006,243(1):135-143.
[11]	Oostendorp M,Douma K,Wagenaar A,et al.Molecular magnetic resonance imaging of myocardial angiogenesis after acute myocardial infarction.Circulation,2010,121(6):775-783.
[12]	Oostendorp M,Douma K,Hackeng TM,et al.Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots.Cancer Res,2008,68(18):7676-7683.
[13]	Petrovic N,Schacke W,Gabagan JR,et al.CD13/APN regulates endothelial invasion and filopedia formation.Blood,2007,110(1):142-150.
[14]	Petrovic N,Bhagwat SV,Ratzan WJ,et al.CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells.J Biol Chem,2003,278(49):49358-49368.
[15]	Ikeda N,Nakajima Y,Tokuhara T,et al.Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma.Clin Cancer Res,2003,9(4):1503-1508.
[16]	Tokuhara T,Hattori N,Ishida H,et al.Clinical significiance of aminopeptidase N in non-small cell lung cancer.Clin Cancer Res,2006,12(13):3971-3978.
[17]	Buehler A,van Zandvoort MA,Stelt BJ,et al.cNGR:a novel horning sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo.Arterioscler Thromb Vasc Biol,2006,26(12):2681-2687.
[18]	Curnis F,Gasparri A,Sacchi A,et al.Targeted delivery of IFN gamma to tumor vessels uncouples antitumor from counter regulatory mechanisms.Cancer Res,2005,65(7):2906-2913.
[19]	Sacchi A,Gasparri A,Curnis F,et al.Crucial role for interferon gamma in the synergism between tumor vaseulature-targeted tumor necrosis factor alpha(NGR-TNF) and doxorubicin.Cancer Res,2004,64(19):7150-7155.
[20]	Curnis F,Sacchi A,Gasparri A,et al.Isoaspartate-glycine-arginine:a new tumor vasculature-targeting motif.Cancer Res,2008,68(17):7073-7082.

[1]	付彤 , 瞿卫 , 王峰 . CD13/氨基肽酶N在新生血管成像中的应用价值. 国际放射医学核医学杂志, 2011, 35(6): 321-324. doi: 10.3760/cma.j.issn.1673-4114.2011.06.001
[2]	潘秀花 , 杨占山 . 促血管生成素的功能及应用进展. 国际放射医学核医学杂志, 2006, 30(1): 53-55.
[3]	郑海燕 . 放疗联合顺铂和多西他赛治疗非小细胞肺癌的临床观察. 国际放射医学核医学杂志, 2009, 33(5): 319-320. doi: 10.3760/cnla.j.issn.1673-4114.2009.05.020
[4]	郝玉美 , 贺欣 , 宋娜玲 . 靶向肿瘤新生血管整合素αvβ3受体显像研究现状及进展. 国际放射医学核医学杂志, 2014, 38(3): 179-184. doi: 10.3760/cma.j.issn.1673-4114.2014.03.010
[5]	杨坤禹 , 胡豫 . 抗肿瘤血管新生联合放射治疗研究进展. 国际放射医学核医学杂志, 2006, 30(2): 122-126.
[6]	王荣福 . 核素示踪靶向肿瘤新生血管分子探针的研究进展. 国际放射医学核医学杂志, 2015, 39(1): 50-54. doi: 10.3760/cma.j.issn.1673-4114.2015.01.011
[7]	李骁扬 , 田野 . 动态增强磁共振成像在抗肿瘤血管药物早期临床试验中的应用. 国际放射医学核医学杂志, 2014, 38(5): 309-314. doi: 10.3760/cma.j.issn.1673-4114.2014.05.008
[8]	陈倩倩 , 张金赫 . 基于树状大分子材料构建的纳米载药体系用于肿瘤靶向治疗的研究进展. 国际放射医学核医学杂志, 2022, 46(5): 304-308. doi: 10.3760/cma.j.cn121381-202106013-00166
[9]	邵国强 , 王自正 . 整合素αvβ3受体靶向肿瘤显像研究进展. 国际放射医学核医学杂志, 2014, 38(1): 33-36. doi: 10.3760/cma.j.issn.1673-4114.2014.01.007
[10]	黄建敏 , 解朋 , 刘晓梅 , 潘莉萍 , 高建青 . 以整合素αvβ3为靶点的肿瘤分子显像及靶向治疗. 国际放射医学核医学杂志, 2015, 39(3): 256-259. doi: 10.3760/cma.j.issn.1673-4114.2015.03.015

点击查看大图

计量

文章访问数: 1636
HTML全文浏览量: 241
PDF下载量: 2

CDl3/氨基肽酶N在新生血管成像中的应用价值

南京医科大学附属南京第一医院核医学科, 210006

收稿日期: 2011-07-12

关键词:

摘要: 新生血管的发生在恶性肿瘤发生、发展和转移过程起着关键作用。CDl3是人类白血病分级的重要谱系特异性标志物,在新生血管内皮细胞上特异性高表达,在静止血管内皮细胞上不表达。利用荧光、核素标记或磁性纳米颗粒耦联CDl3单克隆抗体、配体,通过分子成像技术可有效探测新生血管的发生,为研究血管相关疾病的发生、发展提供影像学依据;CDl3的配体——天冬氨酸.甘氨酸一精氨酸与各种抗肿瘤药物构成复合物,然后转运到肿瘤新生血管内皮细胞表面与CDl3结合,释放抗肿瘤药物治疗肿瘤。CDl3在与新生血管相关的各类疾病的认识、诊断、治疗的研究中有着突破性进展和良好的前景。